Rogel Cancer Center: University of Michigan
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy
- Conditions
- Head and Neck Neoplasms
- Interventions
- Other: MPACT
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02485470
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: MPDL3280ARadiation: Hypofractionated Radiotherapy
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02463994
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Washington, Seattle, Seattle, Washington, United States
A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Radiation: Adaptive Radiation Therapy
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT02460835
- Locations
- 🇺🇸
Rogel Comprehensive Cancer Center, Ann Arbor, Michigan, United States
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02436408
- Locations
- 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
- Conditions
- LymphomaLeukemiaBrain Tumor
- Interventions
- Behavioral: Education information system
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT02409121
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT02400463
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
- Conditions
- Breast Neoplasms
- Interventions
- Other: endocrine therapy alone without radiotherapy
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 202
- Registration Number
- NCT02400190
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Harvard University, Cambridge, Massachusetts, United States
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT02338115
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT02331368
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02328755
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States